BIIB - バイオジェン （Biogen Inc.） バイオジェンBIIBのチャート
BIIBの企業情報
| symbol | BIIB |
|---|---|
| 会社名 | Biogen Inc （バイオジェン） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 バイオジェン(Biogen Inc.)は生物技術会社である。同社は神経学的疾患、希少疾患、自己免疫疾患の治療製品の発見・開発・製造・提供に従事する。同社は多発性硬化症（MS）の治療用「ECFIDERA」、「AVONEX」、「PLEGRIDY」、「TYSABRI」、「ZINBRYTA」、「FAMPYRA」、重症プラーク乾癬の治療用「FUMADERM」、脊髄性筋萎縮症（SMA）の治療用「SPINRAZA」を含む製品を販売する。同社はまた非ホジキンリンパ腫、慢性リンパ球性白血病（CLL）等の治療用「RITUXAN」に関連するRoche GroupのメンバーであるGenentech、Inc.（Genentech）との共同契約を締結して、CLLと濾胞性リンパ腫の治療用「GAZYVA」、他の抗CD20療法を提供する。同社は製品候補はOCREVUS、バイオシミラー・アダリムマブ、Aducanumab、E2609、BIIB074、BAN2401、オピシヌマブ、CIARA、BIIB061、BIIB054、BIIB067、BIIB068を含む。 バイオジェンはバイオ医薬品企業。神経疾患治療の医薬品の開発・製造・販売に従事する。再発性多発性硬化症(MS)治療薬、クロ―ン病治療薬、非ホジキンリンパ腫と関節リウマチ治療薬などが主要製品。また、潰瘍性大腸炎などの自己免疫疾患のほか、血友病、リンパ性白血病、非ホジキンリンパ腫の治療薬も扱う。本社はマサチュ―セッツ州ケンブリッジ。 At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain. |
| 本社所在地 | 225 Binney Street Cambridge MA 02142 USA |
| 代表者氏名 | Stelios Papadopoulos Stelios Papadopoulos |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 781-464-2000 |
| 設立年月日 | 31229 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 7300人 |
| url | www.biogen.com |
| nasdaq_url | https://www.nasdaq.com/symbol/biib |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 6760.6 |
| 終値（lastsale） | 343.03 |
| 時価総額（marketcap） | 69100940835.5 |
| 時価総額 | 時価総額（百万ドル） 69411.16 |
| 売上高 | 売上高（百万ドル） 12872.4 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 72115.36 |
| 当期純利益 | 当期純利益（百万ドル） 4141.8 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Biogen Inc revenues increased 10% to $6.49B. Net income increased 27% to $2.04B. Revenues reflect Product net increase of 5% to $5.28B Revenue Sales of Goods_Services increase of 27% to $933.6M Other Rev from Biz Related Activ. increase from $131.6M to $273M. Net income benefited from Amortization of acquired intangible asse decrease of 63% to $211.3M (expense). |
BIIBのテクニカル分析
BIIBのニュース
Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen 2022/10/17 11:30:00 GlobeNewswire
CAMBRIDGE, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period of the new drug application (NDA) for tofersen by three months. Tofersen is an investigational treatment for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). The updated Prescription Drug User Fee Act (PDUFA) goal date is April 25, 2023.
Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress 2022/10/17 10:30:00 Wallstreet:Online
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today presented additional data from the Phase 3 SKYLARK Study of zuranolone in adult women with postpartum depression (PPD), at the 35th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 15-18, 2022, in Vienna, Austria. This was the first time the SKYLARK Study was presented at a medical congress.
What to know about Roche’s experimental Alzheimer’s treatment 2022/10/17 08:40:55 STAT News
Interest in the readout on gantenerumab has heightened since drugmakers Eisai and Biogen announced positive results for lecanemab.
How Biogen Makes Money In 2022 And How They Defied Gravity 2022/10/15 14:52:28 Bitcoin Ethereum News
The post How Biogen Makes Money In 2022 And How They Defied Gravity appeared on BitcoinEthereumNews.com . | Getty Images Key Takeaways Biogen has seen its stock price skyrocket after groundbreaking news about its new Alzheimer’s treatment that could improve the lives of millions of Americans, and…
Hot Stocks: INMD jumps on preliminary results; DPZ climbs on earnings; PGR falls; BIIB upgrade 2022/10/13 17:20:41 Seeking Alpha
INMD rose on preliminary results. DPZ climbed on earnings news. PGR dipped after publishing monthly performance figures. BIIB rose on an analyst upgrade.
Robert W. Baird Stick to Their Hold Rating for Biogen By Investing.com 2021/10/05 09:11:27 Investing.com
Robert W. Baird Stick to Their Hold Rating for Biogen
Thomasville National Bank Buys Becton, Dickinson and Co, Atmos Energy Corp, Vanguard ... 2021/10/04 22:38:03 GuruFocus
Related Stocks: BDX , BIV , AGG , IXN , SNV , FB , ATO , PZA , PRU , MUB , RHI , NVDA , SCHW , CCBG , T , LLY , PPG , FDN , VFC , IHI , BIIB , VOD , NNN ,
Sage, Biogen''s zuranolone shows potential to reduce depressive symptoms 2021/10/04 11:04:01 Seeking Alpha
Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychopharmacology (ECNP) Congress 2021/10/04 10:30:00 Business Wire
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new data from the LANDSCAPE and NEST clinical development progra
UAE approves use of first, only drug to treat Alzheimer''s 2021/10/03 11:28:06 Khaleej Times
Biogen''s Aduhelm (aducanumab) injections get governemnt go-ahead
STAT+: Pharmalittle: Biogen yanks Alzheimers paper from JAMA over edits; Pfizer sees $33.5 billion in Covid-19 vax sales 2021/07/28 13:38:05 STAT News
Gayle Smith, head of global Covid-19 response at the State Department, urged U.S. vaccine makers to back low-cost manufacturing hubs overseas.
The 9 behind-the-scenes professionals you need to know in digital health 2021/07/28 12:46:44 Business Insider
Summary List Placement Hello, Welcome to Insider Healthcare. I''m Lydia Ramsey Pflanzer, and today in healthcare news: We found 9 players working behind the scenes who can make or break a digital health startup ; It''s back to wearing masks indoors, even for those fully vaccinated, CDC says ; Here''s the presentation Deep Genomics used to raise $180 million from investors including SoftBank and Khosla . If you''re new to this newsletter, sign up here. Comments, tips? Email me at lramsey@insider.com or tweet @lydiaramsey125 . Let''s get to it As coronavirus cases continue to surge in the US fueled by the Delta variant, the CDC introduced new masking guidelines . Everyone should mask up indoors, whether vaccinated or not , in areas of the country at higher risk from the virus. The CDC also recommended that everyone in K-12 schools wear a mask indoors. CDC Director Rochelle Walensky said on Tuesday that new data about Delta had prompted the change from May, when the CDC had said that masks were no longer necessary for fully vaccinated people.
Global Adalimumab Market Will Reach $ 28,508.07 Million by 2027||Players-CELLTRION INC., Samsung Bioepis (a subsidiary of Samsung Biologics), Biogen, Coherus BioSciences, Innovent Biologics, Inc., Mylan N.V., Zydus Cadila 2021/07/28 08:26:43 OpenPR
Adalimumab market report presents the best market and business solutions to Pharmaceutical industry in this rapidly revolutionizing market place to thrive in the market. Market definition gives the scope of particular product with respect to the driving factors and restraints